European Society for Medical Oncology Immuno-Oncology Congress 2022
Format: 122 videos + 314 pdf, size: 15.5 GB
Course Audience: oncologist, immunologist
Overview:
The ESMO Immuno-Oncology Congress took place as an onsite event in Geneva, Switzerland, 7-9 December 2022, as well as online, through a dedicated virtual platform.
The ESMO Immuno-Oncology Congress is a global meeting offering an advanced educational programme and the latest scientific developments in this promising field.
From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress caters to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.
B cells as a therapeutic opportunity Antibody responses in the TME (Video MP4 Format)
B cells as a therapeutic opportunity Antibody responses in the TME (PDF Format)B cells as a therapeutic opportunity B cell function within tertiary lymphoid structures (Video MP4 Format)B cells as a therapeutic opportunity B cell function within tertiary lymphoid structures (PDF Format)B cells as a therapeutic opportunity Q&A (Video MP4 Format)B cells as a therapeutic opportunity Tertiary lymphoid structure formation in non-small cell lung cancer (Video MP4 Format)B cells as a therapeutic opportunity Tertiary lymphoid structure formation in non-small cell lung cancer (PDF Format)Bristol Myers Squibb – Exploring new advancements in chemokine signaling Caught in a NET Reviewing IL-8, CXCR1, and CXCR2 signaling in tumor biology (Video MP4 Format)Bristol Myers Squibb – Exploring new advancements in chemokine signaling Closing remarks and audience Q&A (Video MP4 Format)Bristol Myers Squibb – Exploring new advancements in chemokine signaling Emerging data for targeting IL-8, CXCR1, and or CXCR2 (Video MP4 Format)Bristol Myers Squibb – Exploring new advancements in chemokine signaling Spotlight on I-O Chemokine signaling and its role in tumor development and I-O resistance (Video MP4 Format)Bristol Myers Squibb – Exploring new advancements in chemokine signaling Welcome and introductions (Video MP4 Format)Cancer vaccines Promise or dead end Introduction and first vote (Video MP4 Format)Cancer vaccines Promise or dead end Promise (Video MP4 Format)Cancer vaccines Promise or dead end Promise (PDF Format)Cancer vaccines Promise or dead end Second vote and conclusions (Video MP4 Format)Combination of radiotherapy and immunotherapy is a good idea Introduction and first vote (Video MP4 Format)Combination of radiotherapy and immunotherapy is a good idea Introduction and first vote (PDF Format)Combination of radiotherapy and immunotherapy is a good idea No (Video MP4 Format)Combination of radiotherapy and immunotherapy is a good idea No (PDF Format)Combination of radiotherapy and immunotherapy is a good idea Second vote and conclusions (Video MP4 Format)Combination of radiotherapy and immunotherapy is a good idea Second vote and conclusions (PDF Format)Epigenetic immunomodelling Epigenetic remodelling in melanoma (Video MP4 Format)Epigenetic immunomodelling Epigenetic remodelling in melanoma (PDF Format)Epigenetic immunomodelling Q&A (Video MP4 Format)Epigenetic immunomodelling T cell differentiation (Video MP4 Format)Epigenetic immunomodelling T cell differentiation (PDF Format)final_programme_immuno22hybrid (PDF Format)GI tumours Advancing immunotherapy in hepatocellular carcinoma through rational combinations and biomarkers (Video MP4 Format)GI tumours Advancing immunotherapy in hepatocellular carcinoma through rational combinations and biomarkers (PDF Format)GI tumours New IO combinations and biomarkers in oesophageal and gastric cancers (Video MP4 Format)GI tumours New IO combinations and biomarkers in oesophageal and gastric cancers (PDF Format)GI tumours Q&A (Video MP4 Format)GI tumours Response and resistance in MMR deficient colorectal cancer Insights from mouse and man (Video MP4 Format)GI tumours Response and resistance in MMR deficient colorectal cancer Insights from mouse and man (PDF Format)GI tumours Signals and rational development opportunities for immunotherapy in MMR proficient colorectal cancer (Video MP4 Format)GI tumours Signals and rational development opportunities for immunotherapy in MMR proficient colorectal cancer (PDF Format)GSK The need to advance checkpoint blockade for cancer immunotherapy How does the CD226 Axis regulate antitumor responses (Video MP4 Format)GSK The need to advance checkpoint blockade for cancer immunotherapy How is the CD226 Axis being studied in clinical trials (Video MP4 Format)GSK The need to advance checkpoint blockade for cancer immunotherapy Panel discussion Q&A (Video MP4 Format)GSK The need to advance checkpoint blockade for cancer immunotherapy What is the CD226 Axis (Video MP4 Format)GSK The need to advance checkpoint blockade for cancer immunotherapy Why is there a need to build on current immune checkpoint therapies (Video MP4 Format)GU malignancies Bladder cancer immunotherapy (Video MP4 Format)GU malignancies Bladder cancer immunotherapy (PDF Format)GU malignancies IO in renal cell carcinoma The latest on combining and sequencing (Video MP4 Format)GU malignancies IO in renal cell carcinoma The latest on combining and sequencing (PDF Format)GU malignancies Prostate cancer immunotherapy (Video MP4 Format)GU malignancies Prostate cancer immunotherapy (PDF Format)GU malignancies Q&A (Video MP4 Format)Gynaecological malignancies and breast tumours Breast cancer immunotherapy overview (Video MP4 Format)Gynaecological malignancies and breast tumours Breast cancer immunotherapy overview (PDF Format)Gynaecological malignancies and breast tumours Immunotherapy plus PARP (Video MP4 Format)Gynaecological malignancies and breast tumours Immunotherapy plus PARP (PDF Format)Gynaecological malignancies and breast tumours Q&A (Video MP4 Format)H&N cancers Lessons from neoadjuvant use of immunotherapy before curative-intent surgery (Video MP4 Format)H&N cancers Lessons from neoadjuvant use of immunotherapy before curative-intent surgery (PDF Format)H&N cancers Lessons from novel intra-tumoural therapies in head and neck cancer (Video MP4 Format)H&N cancers Lessons from novel intra-tumoural therapies in head and neck cancer (PDF Format)H&N cancers Lessons from trials of curative-intent (chemo)radiotherapy combined with immunotherapy (Video MP4 Format)H&N cancers Lessons from trials of curative-intent (chemo)radiotherapy combined with immunotherapy (PDF Format)H&N cancers Lessons from trials of systemic immunotherapies in relapsed and or metastatic disease (Video MP4 Format)H&N cancers Lessons from trials of systemic immunotherapies in relapsed and or metastatic disease (PDF Format)H&N cancers Q&A (Video MP4 Format)Haematological malignancies ICI and lymphomas (Video MP4 Format)Haematological malignancies ICI and lymphomas (PDF Format)Haematological malignancies Improving outcomes of cellular therapy in non-Hodgkin’s B-cell lymphoma (Video MP4 Format)Haematological malignancies Improving outcomes of cellular therapy in non-Hodgkin’s B-cell lymphoma (PDF Format)Haematological malignancies Oncolytic virus therapy A novel immunotherapeutic approach in haematologic malignancies (Video MP4 Format)Haematological malignancies Oncolytic virus therapy A novel immunotherapeutic approach in haematologic malignancies (PDF Format)Haematological malignancies Q&A (Video MP4 Format)Imaging biomarkers in IO for cancer AI and radiomics Results in immunotherapy (Video MP4 Format)Imaging biomarkers in IO for cancer AI and radiomics Results in immunotherapy (PDF Format)Imaging biomarkers in IO for cancer MRI techniques to visualise what is happening during immunotherapy (Video MP4 Format)Imaging biomarkers in IO for cancer MRI techniques to visualise what is happening during immunotherapy (PDF Format)Imaging biomarkers in IO for cancer Q&A (Video MP4 Format)Imaging biomarkers in IO for cancer Whole body imaging macrophages (Video MP4 Format)Imaging biomarkers in IO for cancer Whole body imaging macrophages (PDF Format)Innate immune effectors Crosstalk between eosinophils and adaptive immune cells dictates response to immune checkpoint blockade in breast cancer (PDF Format)Innate immune effectors Diversity, function and clinical significance of tumor-associated macrophages (PDF Format)Innate immune effectors Q&A (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Conclusions (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Panel session (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Q&A 1 (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Q&A 2 (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Q&A 3 (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Q&A 4 (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Stromal cells in the TME (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Stromal cells in the TME (PDF Format)Joint ESMO-SITC Immunotherapy Primer The importance of myeloid cells in the TME (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer The importance of myeloid cells in the TME (PDF Format)Joint ESMO-SITC Immunotherapy Primer The microbiome influence on the TME (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer The microbiome influence on the TME (PDF Format)Joint ESMO-SITC Immunotherapy Primer The utility of radiographic imaging and radiotherapy in immunotherapy (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer The utility of radiographic imaging and radiotherapy in immunotherapy (PDF Format)Joint ESMO-SITC Immunotherapy Primer Utilizing oncolytic virus as a new treatment modality (Video MP4 Format)Joint ESMO-SITC Immunotherapy Primer Utilizing oncolytic virus as a new treatment modality (PDF Format)Joint ESMO-SITC Immunotherapy Primer Welcome and introduction (Video MP4 Format)Local therapy for systemic beneficial goals Focal tumour radiotherapy as a trigger for systemic immune response (Video MP4 Format)Local therapy for systemic beneficial goals Focal tumour radiotherapy as a trigger for systemic immune response (PDF Format)Local therapy for systemic beneficial goals Intratumoral tumor-specific treg depletion (Video MP4 Format)Local therapy for systemic beneficial goals Intratumoral tumor-specific treg depletion (PDF Format)Local therapy for systemic beneficial goals Intratumoural oncolytic virotherapy (Video MP4 Format)Local therapy for systemic beneficial goals Intratumoural oncolytic virotherapy (PDF Format)Local therapy for systemic beneficial goals Intratumoural STING agonists (Video MP4 Format)Local therapy for systemic beneficial goals Intratumoural STING agonists (PDF Format)Local therapy for systemic beneficial goals Q&A (Video MP4 Format)Mini Oral session 1 35MO – Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (Video MP4 Format)Mini Oral session 1 35MO – Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (PDF Format)Mini Oral session 1 36MO – Location and size of metastasectomy in melanoma patients treated with tumor-infiltrating lymphocytes (Video MP4 Format)Mini Oral session 1 36MO – Location and size of metastasectomy in melanoma patients treated with tumor-infiltrating lymphocytes (PDF Format)Mini Oral session 1 60MO – Real-World Overall and Progression-Free Survival for First-Line Immunotherapy-Based Regimens (Video MP4 Format)Mini Oral session 1 60MO – Real-World Overall and Progression-Free Survival for First-Line Immunotherapy-Based Regimens (PDF Format)Mini Oral session 1 61MO – IMscin001 (Part 2 Randomized Phase III) Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) (Video MP4 Format)Mini Oral session 1 61MO – IMscin001 (Part 2 Randomized Phase III) Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) (PDF Format)Mini Oral session 1 Invited Discussant 1 (Video MP4 Format)Mini Oral session 1 Invited Discussant 1 (PDF Format)Mini Oral session 1 Invited Discussant 2 (Video MP4 Format)Mini Oral session 1 Invited Discussant 2 (PDF Format)Mini Oral session 1 LBA2 – Phase II study of PD-L1 Expression Guidance on Neoadjuvant (Video MP4 Format)Mini Oral session 1 LBA2 – Phase II study of PD-L1 Expression Guidance on Neoadjuvant (PDF Format)Mini Oral session 1 LBA6 – UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells (PDF Format)Mini Oral session 2 200MO – Anti-IL-8 BMS-986253 nivolumab (NIVO) ipilimumab (IPI) in patients (pts) (Video MP4 Format)Mini Oral session 2 200MO – Anti-IL-8 BMS-986253 nivolumab (NIVO) ipilimumab (IPI) in patients (pts) (PDF Format)Mini Oral session 2 2MO – First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) (Video MP4 Format)Mini Oral session 2 2MO – First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) (PDF Format)Mini Oral session 2 3MO – Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1 L1 immune checkpoint (Video MP4 Format)Mini Oral session 2 3MO – Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1 L1 immune checkpoint (PDF Format)Mini Oral session 2 62MO – Naxitamab Pivotal Clinical Trial Planned Interim Analysis of PFS and OS (Video MP4 Format)Mini Oral session 2 62MO – Naxitamab Pivotal Clinical Trial Planned Interim Analysis of PFS and OS (PDF Format)Mini Oral session 2 Invited Discussant 1 (Video MP4 Format)Mini Oral session 2 Invited Discussant 1 (PDF Format)Mini Oral session 2 Invited Discussant 2 (Video MP4 Format)Mini Oral session 2 Invited Discussant 2 (PDF Format)Mini Oral session 2 Invited Discussant 3 (Video MP4 Format)Mini Oral session 2 Invited Discussant 3 (PDF Format)Mini Oral session 2 LBA1 – Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression (Video MP4 Format)Mini Oral session 2 LBA1 – Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression (PDF Format)Mini Oral session 2 LBA3 – Compartmental Radioimmunotherapy (cRIT) 131I-OMBURTAMAB in Patients with Neuroblastoma (Video MP4 Format)Mini Oral session 2 LBA3 – Compartmental Radioimmunotherapy (cRIT) 131I-OMBURTAMAB in Patients with Neuroblastoma (PDF Format)Next generation technologies for the optimal implementation of immunotherapy Engineering myeloid CAR-M (Video MP4 Format)Next generation technologies for the optimal implementation of immunotherapy Engineering myeloid CAR-M (PDF Format)Next generation technologies for the optimal implementation of immunotherapy Molecular tissue imaging New technologies (Video MP4 Format)Next generation technologies for the optimal implementation of immunotherapy Molecular tissue imaging New technologies (PDF Format)Next generation technologies for the optimal implementation of immunotherapy Multi-specific antibody-like platforms (Video MP4 Format)Next generation technologies for the optimal implementation of immunotherapy Multi-specific antibody-like platforms (PDF Format)Next generation technologies for the optimal implementation of immunotherapy Q&A (Video MP4 Format)Novel clinical and translational insights in melanoma Monitoring and refining melanoma patient care for immunotherapy (Video MP4 Format)Novel clinical and translational insights in melanoma Monitoring and refining melanoma patient care for immunotherapy (PDF Format)Novel clinical and translational insights in melanoma Novel therapeutic immunotherapy modalities in cutaneous melanoma (Video MP4 Format)Novel clinical and translational insights in melanoma Novel therapeutic immunotherapy modalities in cutaneous melanoma (PDF Format)Novel clinical and translational insights in melanoma Q&A (Video MP4 Format)Novel clinical and translational insights in melanoma Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma (PDF Format)Poster Display session 100P – Immunotherapy around the clock impact on stage IV melanoma (PDF Format)Poster Display session 101P – Safety and effectiveness of pembrolizumab (PDF Format)Poster Display session 102P – A Multicenter Retrospective Cohort Study (PDF Format)Poster Display session 103P – Phase IIIb study of durvalumab plus (PDF Format)Poster Display session 104P – Camrelizumab combined with chemotherapy (PDF Format)Poster Display session 105P – Neoadjuvant tislelizumab combined (PDF Format)Poster Display session 106P – Zanubrutinib in combination with tislelizumab (PDF Format)Poster Display session 107P – Outcomes of patients with metastatic non-small-cell lung cancer (PDF Format)Poster Display session 108P – Role of the prognostic nutritional index (PDF Format)Poster Display session 109P – Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety (PDF Format)Poster Display session 10P – Deep Learning-based prediction of patientOs (PDF Format)Poster Display session 110P – Fecal Microbiota Transplantation (PDF Format)Poster Display session 111P – Identification of Atezolizumab plus (PDF Format)Poster Display session 112P – Pseudoprogression predicts better prognosis (PDF Format)Poster Display session 113P – The prognostic and predictive roles of serum (PDF Format)Poster Display session 114P – Systemic Inflammatory Index as a prognostic (PDF Format)Poster Display session 115P – Reflectance Confocal Microscopy – An In Vivo (PDF Format)Poster Display session 116P – Clinical Significance of Serum-derived (PDF Format)Poster Display session 117P – Beta-Blockers in Lung Cancer Patients Receiving Immunotherapy (PDF Format)Poster Display session 118P – Immunosenescence and response to immunotherapy in elderly patients A possible (PDF Format)Poster Display session 119TiP – An observational study to assess the effectiveness (PDF Format)Poster Display session 11P – Association of VISTA expressing CD66b positive (PDF Format)Poster Display session 120TiP – Conversion of Response to Immune Checkpoint Inhibition by Fecal Microbiota (PDF Format)Poster Display session 121TiP – Prospective, single arm, phase II clinical trial of pembrolizumab combined (PDF Format)Poster Display session 123P – IMpower010 exploratory overall survival (OS) (PDF Format)Poster Display session 124P – Phase II Study of Neoadjuvant Concurrent (PDF Format)Poster Display session 125P – A phase 2a study of the novel immunogenic (PDF Format)Poster Display session 126P – AdvanTIG-105 Phase 1b Dose-Expansion Study (PDF Format)Poster Display session 127P – Phase 1 study of fianlimab, a human (PDF Format)Poster Display session 128P – Neoadjuvant durvalumab plus chemotherapy (PDF Format)Poster Display session 129P – Tislelizumab Combined with Bevacizumab Plus (PDF Format)Poster Display session 12P – Multi-omics correlation with clinical outcome (PDF Format)Poster Display session 130P – COM701 Nivolumab – preliminary results of (PDF Format)Poster Display session 131P – First-line HDACi plus Tislelizumab combined (PDF Format)Poster Display session 132P – Randomized Phase 3 Study of Tislelizumab Plus (PDF Format)Poster Display session 133P – Efficacy of Nivolumab Immunotherapy in Non (PDF Format)Poster Display session 134P – Safety and efficacy of multi-target TKI (PDF Format)Poster Display session 135P – Camrelizumab plus chemotherapy as first-line (PDF Format)Poster Display session 136P – Tislelizumab (TIS) plus chemotherapy (chemo) (PDF Format)Poster Display session 137P – Tislelizumab Combined with Chemotherapy as (PDF Format)Poster Display session 138P – Randomized Phase 3 Study of Tislelizumab Plus (PDF Format)Poster Display session 139P – The timing, dynamics, and co-occurrence of (PDF Format)Poster Display session 13P – Tumor infiltrating CD8 CD103 TIM-3-expressing (PDF Format)Poster Display session 140P – Patient-Reported Outcomes (PRO) Following (PDF Format)Poster Display session 141P – Efficacy and Safety of Tislelizumab Combined (PDF Format)Poster Display session 142P – CODAK real-world study Interim analysis of (PDF Format)Poster Display session 143P – Efficacy and safety of bronchial arterial (PDF Format)Poster Display session 144P – Toripalimab plus chemotherapy as neoadjuvant (PDF Format)Poster Display session 145P – Preliminary results of a phase II study of (PDF Format)Poster Display session 146P – Stereotactic body radiotherapy plus anlotinib (PDF Format)Poster Display session 148P – AdvanTIG-105 Phase 1b Dose-Expansion Study (PDF Format)Poster Display session 149P – A phase Ib II trial of surufatinib plus (PDF Format)Poster Display session 14P – Deep learning-based quantification of immune (PDF Format)Poster Display session 150P – Phase 1 study of fianlimab, a human (PDF Format)Poster Display session 151P – Clinical outcome and preliminary immune (PDF Format)Poster Display session 152P – A Phase I Study of HBM4003, an anti-CTLA-4 (PDF Format)Poster Display session 153P – Neoadjuvant therapy with tislelizumab plus (PDF Format)Poster Display session 154P – Neoadjuvant chemotherapy plus tislelizumab (PDF Format)Poster Display session 155P – BNT113 + pembrolizumab as first-line (PDF Format)Poster Display session 156P – A Phase 1b 2 Study of Nanatinostat (Nstat) Plus (PDF Format)Poster Display session 158P – Triple blockade of the DNAM-axis with COM701 (PDF Format)Poster Display session 159P – COM701 in combination with nivolumab (PDF Format)Poster Display session 15P – Prediction for pCR after Neoadjuvant (PDF Format)Poster Display session 160P – COLUMBIA-1 A Phase Ib II, Open-Label (PDF Format)Poster Display session 161P – A Phase 1b Study to Evaluate IK-007 (PDF Format)Poster Display session 162P – Efficacy and safety of GEMOX (PDF Format)Poster Display session 163P – Neoadjuvant Chemoradiotherapy plus (PDF Format)Poster Display session 164P – TQB2450 plus anlotinib combined with paclitaxel (PDF Format)Poster Display session 165P – Efficacy and safety of tislelizumab (PDF Format)Poster Display session 166P – Combination of 5-fluorouracil (FU), interferon (IFN)-alpha2 (PDF Format)Poster Display session 167P – TisCRT-LAPC A phase II clinical trial (PDF Format)Poster Display session 168P – Liver metastases (mets) and treatment effect (PDF Format)Poster Display session 169P – Immunomodulatory effects of RBS2418 (PDF Format)Poster Display session 170P – EO2401 microbiome derived therapeutic vaccine (PDF Format)Poster Display session 171P – Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX (PDF Format)Poster Display session 172P – Phase 1 Study of JTX-8064, a LILRB2 (ILT4) inhibitor (PDF Format)Poster Display session 173P – First-in-human study to evaluate the safety and clinical activity of FS222 (PDF Format)Poster Display session 174P – First-in-human Study of NGM707, An ILT2 ILT4 Dual Antagonist Antibody (PDF Format)Poster Display session 175P – Safety and Preliminary Efficacy of GEN1042 (DuoBody-CD40x4-1BB) (PDF Format)Poster Display session 176P – Phase 1 Study of INCB106385 Alone or in Combination with Immunotherapy (PDF Format)Poster Display session 177P – Targeting of immune regulatory proteins (PDF Format)Poster Display session 178P – Antibody engineering to evaluate binding, internalisation (PDF Format)Poster Display session 179P – Early Proof of Concept of Safety and Clinical (PDF Format)Poster Display session 17P – Using ex vivo organ culture technology to (PDF Format)Poster Display session 180P – Recalling pre-existing microbiota-specific T cells to target tumors (PDF Format)Poster Display session 181P – SELECT- A phase 2 randomized trial evaluating (PDF Format)Poster Display session 182P – Cancer vaccines based on whole-tumor-lysate (PDF Format)Poster Display session 183P – COMMANDER-001 Initial safety data from (PDF Format)Poster Display session 184P – A Phase I Study of the cancer-specific vaccine FMPV-1 (PDF Format)Poster Display session 185P – Interim analysis of the EOGBM1-18 study (PDF Format)Poster Display session 186P – Synergistic antitumor effect of gemcitabine (PDF Format)Poster Display session 187P – Phase 1 2 study of the oral CCR4 antagonist (PDF Format)Poster Display session 188P – IPH5201 as Monotherapy or in Combination (PDF Format)Poster Display session 189P – IL-10 enhances macrophage phagocytosis (PDF Format)Poster Display session 18P – Systematic evaluation of published predictive (PDF Format)Poster Display session 190P – Combination of IPH5201, a blocking antibody (PDF Format)Poster Display session 191P – Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy (PDF Format)Poster Display session 192P – Safety and clinical activity of IOA-244 (PDF Format)Poster Display session 193P – CLAUDIN-1 Targeting Antibodies in Solid Tumors (PDF Format)Poster Display session 194P – Thermal ablation followed by intratumoral injection (PDF Format)Poster Display session 195TiP – A First-In-Human, Phase 1 a b Dose (PDF Format)Poster Display session 196TiP – A Phase 1 study of REGN6569, a GITR monoclonal antibody (mAb) (PDF Format)Poster Display session 197TiP – First-in-human (FIH) Phase 1 2 study (PDF Format)Poster Display session 198TiP – DEDALUS trial a single-arm, phase 2, multi-center (PDF Format)Poster Display session 199TiP – A first-in-human phase I study of IPH5301 (PDF Format)Poster Display session 19P – Effects of CTLA-4 Single Nucleotide (PDF Format)Poster Display session 201P – Phase II study of taminadenant (A2AR antagonist) (PDF Format)Poster Display session 202P – The therapeutic cancer vaccine PDC (PDF Format)Poster Display session 203P – Early remodeling of systemic antitumor T cell (PDF Format)Poster Display session 204P – Tumor immune microenvironment (PDF Format)Poster Display session 205P – Pre-existing tumor host immunity characterization (PDF Format)Poster Display session 206P – Characterization of the immune microenvironment of recurrent (PDF Format)Poster Display session 207P – Impact of Lymphatic Vessel Derived Oxysterol on anti-tumor immunity (PDF Format)Poster Display session 208P – Sex hormones impact the response to immunotherapy in obese male mice (PDF Format)Poster Display session 209P – Single-cell profiling of tumor-associated neutrophils in advanced non-small (PDF Format)Poster Display session 20P – Human virome epitope-level antiviral antibody (PDF Format)Poster Display session 210P – Anti-CTLA-4 overcomes inhibitory effect of PD1high regulatory T cell (PDF Format)Poster Display session 211P – A new role for CXCL3 in shaping the metastatic tumor microenvironment (PDF Format)Poster Display session 212P – Augmenting Cancer Immunotherapy by Targeting the Fes Kinase (PDF Format)Poster Display session 213P – Type-1 diabetes restricts melanoma growth by reprogramming intra-tumoral (PDF Format)Poster Display session 214P – Location matters oral cancer cells at the tumor invasive border that express GARP (PDF Format)Poster Display session 215P – Proteogenomics to guide neoantigen discovery in non-small cell lung cancer (PDF Format)Poster Display session 216P – Relationship between regulatory T lymphocytes (Treg) (PDF Format)Poster Display session 217P – Characterization of immune cells in the tumor microenvironment of advanced bladder cancer (PDF Format)Poster Display session 218P – A symbiotic relationship between persistent (PDF Format)Poster Display session 219P – Spatial sequencing of T cell repertoire in breast cancer (PDF Format)Poster Display session 21P – Peripheral pre-existing T-cell immunity as (PDF Format)Poster Display session 220P – HDAC1 inhibition sensitizes refractory tumor cells to anti-PD-1 (PDF Format)Poster Display session 221P – The role of TNF-alpha in thymus dysfunction during Acute myeloid leukemia (PDF Format)Poster Display session 222P – Platinum-based chemotherapy attenuates the CD8 T cell proliferative response (PDF Format)Poster Display session 223P – Single-cell RNA-seq dissecting the stemness of tumor cells and the tumor (PDF Format)Poster Display session 224P – Immune characterization of de novo metastatic breast cancer (PDF Format)Poster Display session 225P – Ovarian cancer-cell glucocorticoid receptor activity modulates cytokine secretion (PDF Format)Poster Display session 226P – LncRNA DILC and PD-L1 Inhibitors (PDF Format)Poster Display session 227P – The elusive Luminal B breast tumor and the mysterious chemokines (PDF Format)Poster Display session 228P – Modelling T Cell-Vasculature interaction in a high-throughput microfluidic platform (PDF Format)Poster Display session 229P – Identify the impact of SARS-CoV-2 on Lung Cancer tumorigenesis (PDF Format)Poster Display session 22P – Mean platelet volume to lymphocyte ratio (PDF Format)Poster Display session 230P – A novel cross-platform concordance analysis using MultiOmyx and PhenoImager (PDF Format)Poster Display session 231P – Characterization of the tumor microenvironment in a cohort of KRAS (PDF Format)Poster Display session 232P – The efficacy of vasohibin 2 gene expression knockdown and biological relevance (PDF Format)Poster Display session 233P – Tumor characteristics of mixed response upon immune checkpoint inhibition (ICI) (PDF Format)Poster Display session 234P – Oncolytic adenovirus-based therapeutics to reprogram the glioblastoma microenvironment (PDF Format)Poster Display session 235P – Multiplexed Imaging Reveals the Immunomodulatory cGAS as a Predictor (PDF Format)Poster Display session 236P – A novel microfluidic platform for understanding the role of PDAC stroma in immune response (PDF Format)Poster Display session 237P – Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients (PDF Format)Poster Display session 238P – Exploring blood immune cell dynamics (PDF Format)Poster Display session 239P – Survival outcomes predicted by irAEs (PDF Format)Poster Display session 23P – Enriching for response patient selection (PDF Format)Poster Display session 240P – AMU Using mRNA Embedding in Transformer Network (PDF Format)Poster Display session 241P – Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy (PDF Format)Poster Display session 242P – Educational needs of healthcare professionals using immune checkpoint inhibitors (PDF Format)Poster Display session 243P – Skin biopsies for pharmacodynamic studies of tebentafusp, a novel bispecific (PDF Format)Poster Display session 244P – DNA-PK inhibition sustains immune activation in SCLC (PDF Format)Poster Display session 24P – The predictive and prognostic role of single (PDF Format)Poster Display session 26P – Impact of SF3B1 mutation on response to immunotherapy (PDF Format)Poster Display session 27P – Gene ontology enrichment analysis of peripheral (PDF Format)Poster Display session 28P – Epithelial Mesenchymal transition confers (PDF Format)Poster Display session 29P – Circulating proteins associated with (PDF Format)Poster Display session 30P – Frequency of peripheral CD8+ T cells expressing (PDF Format)Poster Display session 31P – The IOpener study tyrosine kinase activity (PDF Format)Poster Display session 32P – Discovering markers that identify pro-metastatic immune cell subsets (PDF Format)Poster Display session 33P – Changes in serum cytokine CXCL12 level can (PDF Format)Poster Display session 34TiP – Prospective Analysis of INteStinal Microbiome (PDF Format)Poster Display session 39P – The expanded CD8+ tumor-infiltrating (PDF Format)Poster Display session 40P – Can we predict which TIL products will react (PDF Format)Poster Display session 41P – Single-Cell Signalling Analysis of Engineered (PDF Format)Poster Display session 42P – Tumor-reactive CD8+ T cells in ovarian and colon cancer in tumors and cell products (PDF Format)Poster Display session 43P – Development of a production process to (PDF Format)Poster Display session 44P – In situ CAR Therapy Using oRNA Lipid (PDF Format)Poster Display session 45P – The RevCAR T cell platform a switchable (PDF Format)Poster Display session 46P – Development of an allogeneic CAR-T targeting MUC1-C (PDF Format)Poster Display session 47P – Phase 1 Study to Assess the Safety and Efficacy (PDF Format)Poster Display session 48P – Phase II trial on vaccination with Autologous (PDF Format)Poster Display session 49P – Exploiting multi-omic integrated data from DC-vaccinated (PDF Format)Poster Display session 4P – FDG PET derived Metabolic Tumor Volume (MTV) (PDF Format)Poster Display session 50P – Enhancing TIL and NK cells adoptive therapies (PDF Format)Poster Display session 51P – Immunological analysis of blood from patients (PDF Format)Poster Display session 52P – MUC1 targeted immunotherapy with an oncolytic adenovirus coding (PDF Format)Poster Display session 53P – Combining cancer vaccines based on arenavirus (PDF Format)Poster Display session 54P – Oncolytic virus combined PD-1 antibody (PDF Format)Poster Display session 55P – Mutations Localized at the Membrane Predict Immunotherapeutic Efficacy in Cancer Treatment (PDF Format)Poster Display session 5P – Tumor microenvironment cellular crosstalk (PDF Format)Poster Display session 63P – Activity and safety of first-line treatments for advanced melanoma (PDF Format)Poster Display session 64P – Safety and efficacy of immune checkpoint inhibitors (PDF Format)Poster Display session 65P – Atezolizumab plus bevacizumab versus (PDF Format)Poster Display session 66P – Real-world data of first-line chemo-immunotherapy (PDF Format)Poster Display session 67P – Real Word Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma (PDF Format)Poster Display session 69P – A Real-World Analysis of Treatment-Free survival for Advanced Melanoma (PDF Format)Poster Display session 6P – Response and survival according to the (PDF Format)Poster Display session 70P – A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal (PDF Format)Poster Display session 71P – Real-world Treatment Patterns and Clinical Outcomes for patients received Sintilimab (PDF Format)Poster Display session 72P – Treatments response in non-small cell lung (PDF Format)Poster Display session 73P – A randomized phase II study of neoadjuvant (PDF Format)Poster Display session 74P – The safety, tolerability, and preliminary (PDF Format)Poster Display session 75P – Effectiveness and safety data from IMreal Cohort 1 (PDF Format)Poster Display session 76P – Safety profile of adjuvant pembrolizumab (PDF Format)Poster Display session 77P – A Study to Evaluate the Safety, Tolerability and (PDF Format)Poster Display session 78P – Clinical outcomes with atezolizumab plus (PDF Format)Poster Display session 79P – Efficacy and Safety of Zimberelimab (GLS-010) (PDF Format)Poster Display session 7P – PrimeCUTR Identifying clinically relevant (PDF Format)Poster Display session 80P – Penpulimab (Anti-PD-1) combined with anlotinib (PDF Format)Poster Display session 81P – Is PD-1 inhibitor based treatment better than (PDF Format)Poster Display session 82P – Preliminary analysis of tislelizumab (TIS) (PDF Format)Poster Display session 83P – The Immune-related adverse event (IRAE) (PDF Format)Poster Display session 84P – Ambulatory management of ICI-induced (PDF Format)Poster Display session 85P – Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy (PDF Format)Poster Display session 86P – Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (PDF Format)Poster Display session 87P – Infliximab use in patients with checkpoint inhibitor toxicities (PDF Format)Poster Display session 88P – Hepatic arterial infusion chemotherapy(HAIC) (PDF Format)Poster Display session 89P – Durvalumab could be effective in combination (PDF Format)Poster Display session 8P – Phenotypic characterization of infused tumor-infiltrating lymphocytes (PDF Format)Poster Display session 90P – Long-term outcomes in melanoma patients (PDF Format)Poster Display session 91P – Association between weight variation (PDF Format)Poster Display session 92P – NEoadjuvant multimodality RX including (PDF Format)Poster Display session 93P – Cetuximab-based chemotherapy after (PDF Format)Poster Display session 94P – Does hyperprogressive disease predict poor survival (PDF Format)Poster Display session 95P – A phase II study of combination of H101 (PDF Format)Poster Display session 96P – Long-term outcomes after initial disease progression with anti-PD-1 in melanoma (PDF Format)Poster Display session 97P – Toxicity of bispecific antibody glofitamab in patients with aggressive B-cell non-Hodgkin (PDF Format)Poster Display session 98P – First-line atezolizumab durvalumab plus (PDF Format)Poster Display session 99P – Sintilimab plus nab-paclitaxel in platinum-refractory (PDF Format)Predictive factors for T cell therapy Q&A (Video MP4 Format)Predictive factors for T cell therapy Radiotherapy and T cell infiltration into tumours (PDF Format)Predictive factors for T cell therapy T cells in clinical immunotherapy for gynaecological cancers (Video MP4 Format)Predictive factors for T cell therapy T cells in clinical immunotherapy for gynaecological cancers (PDF Format)Predictive factors for T cell therapy The dynamics of T cell receptor signalling in cancer immunotherapy (Video MP4 Format)Predictive factors for T cell therapy The dynamics of T cell receptor signalling in cancer immunotherapy (PDF Format)Proffered Paper session 1O – IMpower010 ctDNA status in patients (pts) (Video MP4 Format)Proffered Paper session 1O – IMpower010 ctDNA status in patients (pts) (PDF Format)Proffered Paper session 56O – A randomized, controlled, multicenter phase II (Video MP4 Format)Proffered Paper session 56O – A randomized, controlled, multicenter phase II (PDF Format)Proffered Paper session 57O – Randomized Double-Blind Phase II Trial (PERLA) (Video MP4 Format)Proffered Paper session 57O – Randomized Double-Blind Phase II Trial (PERLA) (PDF Format)Proffered Paper session 58O – Real-world overall survival (OS) with durvalumab (Video MP4 Format)Proffered Paper session 58O – Real-world overall survival (OS) with durvalumab (PDF Format)Proffered Paper session Invited Discussant 1 (Video MP4 Format)Proffered Paper session Invited Discussant 1 (PDF Format)Proffered Paper session Invited Discussant 2 (Video MP4 Format)Proffered Paper session Invited Discussant 2 (PDF Format)Proffered Paper session Invited Discussant 3 (Video MP4 Format)Proffered Paper session Invited Discussant 3 (PDF Format)Proffered Paper session LBA4 – Preliminary safety and efficacy of adagrasib (Video MP4 Format)Proffered Paper session LBA4 – Preliminary safety and efficacy of adagrasib (PDF Format)Proffered Paper session LBA5 – A phase 2 study of neoadjuvant SHR-1701 (Video MP4 Format)Proffered Paper session LBA5 – A phase 2 study of neoadjuvant SHR-1701 (PDF Format)Session in collaboration with SITC Moving beyond just T cells in the TME Conclusions (Video MP4 Format)Session in collaboration with SITC Moving beyond just T cells in the TME Panel discussion (Video MP4 Format)Session in collaboration with SITC Moving beyond just T cells in the TME Welcome and introduction (Video MP4 Format)Shared and neoantigen vaccines and T cells Lessons learned from dendritic cell vaccines (Video MP4 Format)Shared and neoantigen vaccines and T cells Lessons learned from dendritic cell vaccines (PDF Format)Shared and neoantigen vaccines and T cells Neoantigen reactive T cells plays a critical role in immunotherapy (PDF Format)Shared and neoantigen vaccines and T cells Q&A (Video MP4 Format)The future of CNS tumors Learning from failures and driven by biology Future perspectives on brain tumours’ treatment (Video MP4 Format)The future of CNS tumors Learning from failures and driven by biology Future perspectives on brain tumours’ treatment (PDF Format)The future of CNS tumors Learning from failures and driven by biology Q&A (Video MP4 Format)The future of CNS tumors Learning from failures and driven by biology Successes, pitfalls, and failures A clinical perspective (Video MP4 Format)The future of CNS tumors Learning from failures and driven by biology Successes, pitfalls, and failures A clinical perspective (PDF Format)The future of CNS tumors Learning from failures and driven by biology The immune microenvironment of primary and metastatic brain tumours (Video MP4 Format)The future of CNS tumors Learning from failures and driven by biology The immune microenvironment of primary and metastatic brain tumours (PDF Format)The future of CNS tumors Learning from failures and driven by biology The integrated genomic and epigenomic landscape of brain tumours (Video MP4 Format)The future of CNS tumors Learning from failures and driven by biology The integrated genomic and epigenomic landscape of brain tumours (PDF Format)Thoracic tumours Beyond PD(L)1 in thoracic tumors Novel targets and combinations (Video MP4 Format)Thoracic tumours Beyond PD(L)1 in thoracic tumors Novel targets and combinations (PDF Format)Thoracic tumours Building on CAR-T experience in mesothelioma (Video MP4 Format)Thoracic tumours Building on CAR-T experience in mesothelioma (PDF Format)Thoracic tumours Immune dynamics during lung cancer development, from premalignant to invasive (Video MP4 Format)Thoracic tumours Immune dynamics during lung cancer development, from premalignant to invasive (PDF Format)Thoracic tumours Optimal integration of immunotherapy in the (neo)adjuvant setting (Video MP4 Format)Thoracic tumours Optimal integration of immunotherapy in the (neo)adjuvant setting (PDF Format)Thoracic tumours Q&A (Video MP4 Format)Tumour and immunometabolism Microbiota and nutrition to module I-O efficacy (PDF Format)Tumour and immunometabolism Q&A (Video MP4 Format)Tumour and immunometabolism Regulation of inflammation by metabolites and nutrients in the tumor niche (Video MP4 Format)Tumour and immunometabolism Regulation of inflammation by metabolites and nutrients in the tumor niche (PDF Format)Tumour microenvironment Q&A (Video MP4 Format)Tumour microenvironment The role of the tumour microenvironment in oncolytic virotherapy for myeloma (Video MP4 Format)Tumour microenvironment The role of the tumour microenvironment in oncolytic virotherapy for myeloma (PDF Format)Tumour microenvironment Tumour-associated macrophages in breast cancer (PDF Format)Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Introduction to the 2022 Award keynote lecture (Video MP4 Format)Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Introduction to the 2022 Award keynote lecture (PDF Format)Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Welcome (Video MP4 Format)Welcome to the ESMO Immuno-Oncology Congress 2022 and Award Welcome (PDF Format)YO Mentorship 2 Setting up first-in-human experimental trials in immuno-oncology (PDF Format)